Stock Groups

UK adds nerve disorder as rare side-effect of AstraZeneca COVID-19 vaccine -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: A physician prepares AstraZeneca CoVID-19 vaccine during the Coronavirus Disease outbreak in Ronquieres. This was done at a vaccination facility. REUTERS/Yves Herman

(Reuters) – The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca (NASDAQ:) COVID-19 vaccine, updates on the agency’s website showed on Thursday.

After GBS was added to the European Medicines Agency’s list of possible side effects last month, Medicines and Healthcare Products Regulatory Agency (MHRA) has taken the decision.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts, or buy/sell signal information. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]